Pilot study of formestane in postmenopausal women with breast cancer.
A pilot study of Formestane or 4-Hydroxyandrostenedione (Lentaron), a new endocrine agent, was conducted on 18 postmenopausal patients with locally advanced and metastatic breast cancer. 16 patients were evaluable for response and objective responses were seen in 4 patients (25%). Stabilisation of disease was seen in 5 patients (32%). Out of 17 patients evaluable for toxicity, 3 (18%) reported adverse effects including hot flushes, lethargy and myalgia. Adverse effects were mild, transient and no patient required discontinuation of drug. Our study confirms that Formestane is a well tolerated endocrine agent with low toxicity and reasonable efficacy in postmenopausal patients with locally advanced and metastatic breast cancer.
Joseph
J K
JK
Institute of Radiotherapy and Oncology, Hospital Kuala Lumpur, Jalan Pahang, Malaysia.
Lim
A K
AK
D000368:Aged; D000369:Aged, 80 and over; D000735:Androstenedione / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010865:Pilot Projects; D017698:Postmenopause
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D000735:Androstenedione; C014594:formestane